InSysBio announces its participation in AGAH Conference 2026 (The Association for Applied Human Pharmacology) which is to be held from February 25-26, 2026 in Frankfurt, Germany. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, is going to present a poster selected for the Poster Pitch at Session 4 Poster Slam:
Thursday, February 26, 09:10–09:15
"Optimization of step-up dosing regimen of T-cell engagers to mitigate cytokine release syndrome using quantitative systems pharmacology modeling: tarlatamab case study" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | December 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Dec 2021 13:02
The launch of fIVE DB facilitates calibration of biomodels
InSysBio now presents its new QSP modeling tool, fIVE DB. The name of the database derives from In Vitro Experiments DataBase. fIVE DB is a repository of kinetic data for Systems Biology Modeling.
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
1.
23 Dec 2021 17:13
InSysBio to update CYTOCON DB and CYTOCON DB Open
CYTOCON DB is a database of human baseline concentrations of cytokines and cells measured in different tissues. CYTOCON DB Open is a version of the database designed for public use.
|
24
|
25
|
26
|
|
27
|
28
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
